Company news

Xencor, Inc. news in 2026

Xencor, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Xencor Reports Third Quarter 2026 Financial Results

November 4, 2026

Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors

October 25, 2026

Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

October 19, 2026

Xencor to Present at the 2026 Cantor Global Healthcare Conference

September 2, 2026

Xencor Reports Second Quarter 2026 Financial Results

August 5, 2026

Xencor to Receive $105 Million from Alexion to Resolve Ultomiris U.S. Royalty Matter

July 30, 2026

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

July 29, 2026

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

July 17, 2026

Xencor Reports First Quarter 2026 Financial Results

May 5, 2026

Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW

May 4, 2026

Xencor Announces Change to Ultomiris® Royalty Revenue Forecast

March 3, 2026

Xencor Reports Fourth Quarter and Full Year 2025 Financial Results

February 24, 2026

Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

January 8, 2026

Calls in 2026

Decks in 2026